

## Clinical Policy: Antiparasitics, Topical

Reference Number: PHW.PDL.122

Effective Date: 01/01/2020

Last Review Date: 07/2023

[Revision Log](#)

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of PA Health and Wellness<sup>®</sup> that Topical Antiparasitics are **medically necessary** when the following criteria are met:

### I. Requirements for Prior Authorization of Antiparasitics, Topical

#### A. Prescriptions That Require Prior Authorization

Prescriptions for non-preferred Antiparasitics, Topical must be prior authorized. See the Preferred Drug List (PDL) for the list of preferred Antiparasitics, Topical at: <https://papdl.com/preferred-drug-list>

#### B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Antiparasitic, Topical, the determination of whether the requested prescription is medically necessary will take into account whether the recipient:

1. For Lindane, **all** of the following:
  - a. Has a documented history of therapeutic failure, contraindication, or intolerance of each of the preferred Antiparasitic, Topical approved or medically accepted for the member's diagnosis,
  - b. Weighs  $\geq 50$  kilograms
  - c. Does not take medication that may reduce the seizure threshold (such as but not limited to; Meperidine, Cyclosporine, Theophylline)

**AND**

2. For all other non-preferred Antiparasitics, Topical, has a history of therapeutic failure, contraindication, or intolerance of the preferred Antiparasitics, Topical approved for medically accepted for the member's diagnosis.

NOTE: If the member does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member, the request for prior authorization will be approved.

**C. Clinical Review Process**

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B above to assess the medical necessity of the request for a prescription for an Antiparasitic, Topical. If the guidelines in Section B are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

**D. Approval Duration:**

Requests for prior authorization of Antiparasitics, Topical will be approved for a dose and duration of therapy consistent with FDA-approved package labeling.

**E. References:**

1. Lindane Lotion/Shampoo [package insert]. Livonia, MI: Major; 2003
2. Eurax [package insert]. Buffalo, NY: Bristol Myers Squibb; May 1991
3. Permethrin Cream [package insert]. Bronx, NY: Clay-Park Labs; October 2002
4. Nix Lice Treatment [package insert]. New York, NY: Pfizer Consumer; 2003
5. Ovide Lotion [package insert]. Hawthorne, NY: TaroPharma U.S.A.,Inc.; 2005
6. Frankowski BL, Weiner LB, American Academy of Pediatrics. Head Lice. Pediatrics. 2002; 110:638-643.
7. Lebwohl M, Clark L, Levitt J. Therapy for head lice based on life cycle, resistance, and safety considerations. Pediatrics. 2007;119(5):965-974.
8. Rauch AE, Kowalsky SF, Lesar TS, Sauerbier GA et al. Lindane(Kwell)-induced aplastic anemia. Arch Intern Med. 1990 Nov;150(11):2393-5.
9. Salavastu CM, Chosidow O, Janier M, Tiplica GS. European guideline for the management of pediculosis pubis. Journal of the European Academy of Dermatology and Venereology. September 2017; 31(9):1425-1428.
10. Goldstein AO, Goldstein BG. Pediculosis pubis and pediculosis ciliaris. UpToDate Inc. Updated March 24, 2021. Accessed August 11, 2021.

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021 annual review: no changes.	01/2021
Q1 2022: policy revised according to DHS revisions effective 01/03/2022	10/2021
Q1 2023 annual review: no changes.	11/2022
Q3 2023: policy revised according to DHS revisions effective 07/10/2023	07/2023